BONE BIOLOGICS CORPORATION: 2025 ANNUAL REPORT – KEY HIGHLIGHTS FOR INVESTORS
Overview and Business Update
Bone Biologics Corporation (“Bone Biologics” or “the Company”), a Delaware-based medical device and biologics company, has released its Form 10-K Annual Report for the fiscal year ended December 31, 2025. The company is listed on the Nasdaq Capital Market under the ticker symbol BBLG, with 1,795,260 shares of common stock outstanding as of February 23, 2026, each with a par value of \$0.001.
The Company is primarily engaged in developing NELL-1/DBM, a novel bone regeneration product. The lead product candidate, NELL-1/DBM, is in clinical development and targets spinal fusion and other bone regeneration indications. The Company remains in a pre-commercial stage, with ongoing regulatory and clinical activities.
Key Financial and Corporate Developments
- Public Float: As of June 30, 2025, the approximate aggregate market value of Bone Biologics’ common equity held by non-affiliates was \$7,232,186.
- Reverse Stock Split: Effective June 10, 2025, the Company implemented a 1-for-6 reverse split of its outstanding common stock. This is a significant corporate action that may impact share price and liquidity.
- Listing and Trading: Both common stock and warrants to purchase common stock are actively traded on Nasdaq under the symbols BBLG and BBLGW, respectively.
- Going Concern: The Company reports recurring operating losses, which have raised “substantial doubt” regarding its ability to continue as a going concern. This is a material uncertainty for current and prospective shareholders.
- Capital Requirements: Bone Biologics acknowledges long-term capital requirements are subject to numerous risks and expects operating expenses to increase as clinical and regulatory development continues.
Product Development and Regulatory Progress
-
NELL-1/DBM Clinical Development: The Company is focused on advancing its NELL-1/DBM lead candidate through the clinical and regulatory pathway. Key milestones and contingent payments under license agreements include:
- \$100,000 upon enrollment of the first subject in a Feasibility Study.
- \$500,000 upon Pre-Market Approval (PMA) of a Licensed Product or Method.
- \$1,000,000 upon the first commercial sale of a Licensed Product or Method.
- \$2,000,000 due upon cumulative net sales reaching \$100,000,000.
- Regulatory Pathway: Progressing to human clinical trials requires the submission and effectiveness of one or more Investigational Device Exemptions (IDEs) with the FDA. Subsequent steps include the execution of clinical trials, submission of a PMA, and potential commercialization.
Risks and Shareholder Considerations
- Limited Operating History: The Company is in a development stage, with limited revenues and a history of operating losses. There is no assurance of achieving profitability in the near term.
- Dependence on Regulatory and Clinical Success: The value of Bone Biologics is heavily dependent on the successful development, regulatory approval, and commercialization of NELL-1/DBM. Delays, failures, or unexpected regulatory hurdles could materially impact the Company’s valuation.
- Financing Risk: Continued operations depend on Bone Biologics’ ability to raise additional capital. Failure to do so may result in delays or termination of development programs.
- Product Liability and Manufacturing Risks: The Company relies on third-party manufacturers and is exposed to risks related to product liability and the supply chain.
- Stockholder Dilution: Additional financings, including possible stock or warrant issues, could dilute existing shareholders.
Corporate Information
Bone Biologics Corporation
2 Burlington Woods Drive, Suite 100
Burlington, MA 01803
Phone: (781) 552-4452
Website: www.bonebiologics.com
Table of Contents and Business Focus
The report includes detailed sections on Business (Item 1), Risk Factors (Item 1A), Legal Proceedings, Management’s Discussion and Analysis, Financial Statements, and more. Notable for investors is the explicit focus on regulatory milestones, capital requirements, and the strategic importance of the NELL-1/DBM product pipeline.
Conclusion
Price-Sensitive Takeaways: The reverse stock split, ongoing capital needs, going concern warning, and the Company’s dependence on the success of NELL-1/DBM are highly material to investors. Progress toward clinical and regulatory milestones, as well as any financing developments, remain the most significant potential drivers of share price.
Disclaimer: This article is a summary interpretation based on Bone Biologics Corporation’s 2025 Annual Report (Form 10-K). It is not investment advice. Investors should review the full filing and consult with financial advisors before making investment decisions. The Company’s future performance is subject to significant risks, and past performance is not indicative of future results.
